NSRX NASUS PHARMA LTD

Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference

Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference

TEL AVIV, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced that company management will present at the H.C. Wainwright 27th Annual Global Investment Conference.

  • Location: Virtual
  • Date: September 5, 2025
  • Time: 07:00-07:30 a.m. ET
  • Type: Company presentation        
  • Presenter: Dan Teleman, Chief Executive Officer
  • Webcast: Registration

Nasus management will be available for one-on-one meetings during the conference. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.

About Nasus Pharma

Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus’s intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle free, easy to use alternatives. Nasus proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products.

Contact



Nasus Pharma Ltd. Israel

Investor Contact

Mike Moyer

LifeSci Advisors





EN
02/09/2025

Underlying

NSRXNASUS PHARMA LTD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NASUS PHARMA LTD

 PRESS RELEASE
Free
NSRX NASUS PHARMA LT...

Nasus Pharma to Participate in Upcoming Investor Conferences

Nasus Pharma to Participate in Upcoming Investor Conferences TEL AVIV, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Company management will participate in upcoming investor conferences in February and March. Oppenheimer 36th Annual Healthcare Life Sciences Conference Date and time: February 25, 2026, 1:20 p.m. ETLocation: Virtual ( )Format: Company presentationSpeaker: Dan Teleman, Chief Executive Officer BIO I...

February 20, 2026 1 EN
 PRESS RELEASE
Free
NSRX NASUS PHARMA LT...

Nasus Pharma to Present Data Highlighting Superior Nasal Deposition an...

Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026 TEL AVIV, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that upcoming data for NS002, the Company’s investigational intranasal epinephrine powder formulation, will be presented at AAAAI 2026 Annual Meeting, taking place in Philadelphia, PA, USA, February 27 to March 2. “We are excited to sha...

February 17, 2026 1 EN
 PRESS RELEASE
Free
NSRX NASUS PHARMA LT...

Nasus Pharma Announces Closing of $15.0 Million Private Placement

Nasus Pharma Announces Closing of $15.0 Million Private Placement TEL AVIV, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the closing of its previously announced private placement of ordinary shares and warrants to purchase ordinary shares for aggregate gross proceeds of approximately $15.0 million, before deducting placement agent fees and other offering expenses. Citizens Capital Markets acted as lead placement agent...

February 13, 2026 1 EN
 PRESS RELEASE
Free
NSRX NASUS PHARMA LT...

Nasus Pharma Announces Pricing of $15.0 Million Private Placement

Nasus Pharma Announces Pricing of $15.0 Million Private Placement TEL AVIV, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that it has entered into a securities purchase agreement (the “Agreement”) with certain institutional and accredited investors for a private placement of ordinary shares and warrants to purchase ordinary shares for aggregate gross proceeds of approximately $15.0 million, before deducting plac...

February 11, 2026 1 EN
 PRESS RELEASE
Free
NSRX NASUS PHARMA LT...

Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical ...

Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder Interim results indicate NS002 demonstrated significantly faster absorption and higher peak epinephrine levels compared to EpiPen® 91% of study participants achieved the 100 pg/ml plasma threshold at 5 minutes with NS002 compared to 67% with EpiPen®   NS002 was well-tolerated with no serious adverse events reported, and a pharmacodynamic response comparable to EpiPen® Full Phase 2 results expected by the end of first quarter of 2026; Pivotal study initiation planned for fou...

January 20, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch